Kornimate/medical-research-clean huggingface dataset:
efficacy & safety of stg320 sublingual tablets of hdm allergen extracts in adults and adolescents with hdm-associated ar

Conditions: Rhinitis, Allergic, Perennial; House Dust Mite Allergy

Summary: the objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 ir of stg320 sublingual tablets compared with placebo in adults and adolescents with hdm-associated allergic rhinitis.

this study was a randomized, double-blind, placebo-controlled, phase iii study with 2 parallel arms in adults and adolescents with hdm-associated allergic rhinitis (ar) for at least one year. the primary objective was to assess the efficacy of stg320 sublingual tablets at a daily dosage of 300 ir when administered for 12 months to adults and adolescents with hdm-associated ar. the primary efficacy variable was the average total combined score.

Eligibility criteria:
main inclusion criteria: * patients with hdm-associated allergic rhinitis (ar) for at least 1 year * patients sensitized to d. pteronyssinus (d. pte) and/or d. farinae (d. far) defined on skin prick test and hdm-specific serum ige main exclusion criteria: * a history of rhinitis, rhinoconjunctivitis or asthma to allergens other than hdm, likely to result in rhinitis symptoms during the evaluation periods * partly controlled or uncontrolled asthma * controlled asthma requiring controller treatment(s) consistent with gina 2014 treatment steps 3 to 5
oral photographs of patients on oral hygiene motivation

Conditions: Periodontal Diseases; Motivation; Hygiene

Summary: based on these considerations, this randomized controlled trial aimed to determine the effectiveness of a personalized visual oral health education program in addition to conventional education on oral hygiene by comparing changes in clinical periodontal parameters. participants will get conventional oral hygiene education (cohe) with/without visual motivation using self oral photographs of patients. researchers will compare intervention group and control groups on oral hygiene by comparing changes in clinical periodontal parameters.

maintaining oral health requires a motivated patient. the adherence to a lifelong oral hygiene regimen is significantly influenced by an individual's motivation and manual dexterity. the physician's responsibility in this context is to provide guidance to the patient regarding the appropriate and efficient oral hygiene routine, as well as to motivate their adherence to it. the definition of motivation is to stimulate action or effort towards a particular goal or objective. motivation is a condition that can be altered in response to external influences and time, rather than being a characteristic. the primary objective of motivation is to enhance persons' knowledge of this matter by highlighting oral health, introducing oral hygiene, and offering information on efficacious mechanical cleaning procedures for eliminating factors that contribute to the deterioration of oral hygiene. participants were divided into 2 groups using https://www.randomizer.org/ website: control group (cg) (n=28): conventional oral hygiene education (cohe) \[22\] intervention group (ig) (n=28): in addition to cohe, the following steps were followed: * session 1: a photograph was taken before (f1) and after (f2) full-mouth scaling root planing (fmsrp). then the patient was shown the difference. * 2nd session: a photograph was taken (f3) and the patient is shown the difference between f1 and f3. * 3rd session: a photograph was taken (f4) and the patient is shown the difference between f1 - f3 - f4.

Eligibility criteria:
inclusion criteria: * age ranging from 18-60 years; * a minimum of 12 teeth; * and being available for the follow-up assessment * participants were wanted to be right-handers when toothbrushing to standardization. exclusion criteria: * patients with systemic illnesses or conditions, * smokers and individuals taking any medication that may affect periodontal health were not included in the study. * individuals who had previously been treated for periodontal disease in the past 6 months were also excluded.

Keywords: oral hygiene periodontal health periodontal indices motivation modified bass technique
replacement of lamivudine by telbivudine to improve renal function

Conditions: Disorder Related to Transplantation; Virus Diseases; Injury Due to Exposure to External Cause

Summary: nephrotoxicity is one of the adverse effects of lamivudine and dosage of lamivudine has to be reduced if patients' renal function is insufficiency. telbivudine may improve glomerular filtration rate. this study is to see whether renal function is improved when lamivudine is replaced by telbivudine in liver transplantation patients.

liver transplantation is the only effective treatment for the patients with liver failure. hepatitis b-related liver cirrhosis is the major indication to have liver transplantation in taiwan. after liver transplantation, prophylaxis of hepatitis b recurrence will be performed by anti-hepatitis b immunoglobulin and anti-viral agents. currently, lamivudine is the drug the investigators choose to prevent hbv recurrence for many years because it is safe for long-term use. however, nephrotoxicity is one of the adverse effects of lamivudine and dosage of lamivudine has to be reduced if patients' renal function is insufficiency. recently, the studies on chronic hepatitis b patients showed improvement of glomerular filtration rate for those receiving telbivudine treatment. in this study, the investigators will include our post-transplant hbv patients who have stable liver function, receive lamivudine for prophylaxis of recurrent hepatitis b, and have renal dysfunction in stage ii-iv. the patients will be randomized to receive telbivudine or lamivudine continuously at 1:1 ratio. renal function will be examined at 6 months interval to determine whether renal function is improved. the achievement will determine whether telbivudine is better than lamivudine for the hbv patients with renal dysfunction.

Eligibility criteria:
inclusion criteria: 1. sign inform consent 2. age is not less than 16 years old. 3. post liver transplantation patient for hbv-related indication. 4. chronic hepatitis b transplant patients who are treated by lamivudine for not less than 6 months. 5. egrf stage 2-4 patients (15\<egfr\<90ml) 6. stable liver function, alt not more than 2 folds of upper limit. exclusion criteria: 1. acute rejection with increase cni dose within a month. 2. pregnant or nursing.
brain imaging, heart rate variability and serum fatty acid in subjects with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: this study is to analyze the relationship between brain structure, the heart rate variability and the serum fatty acid component of the irritable bowel syndrome patients.

several studies showed that the gray matter and white matter of the brain related to the symptoms of irritable bowel syndrome patients. the investigators study is to analyse the relationship between thickness of cortex of irritable patients, the sympathetic tone and the serum fatty acid component of the irritable bowel syndrome patients. it is to clarify the mechanism of irritable bowel syndrome, whether the symptoms of irritable bowel syndrome are related to the thickness of cortex or inflammation status of the body.

Eligibility criteria:
inclusion criteria: * female * between 20 and 50 years old * meet rome iii criteria exclusion criteria: * colon and small intestinal disease * psychiatric disease patients * patients received major surgery in the past 5 years * diabetic patients * patients with metal implant

Keywords: mri heart rate variability fatty acid
combined intense pulsed light (ipl) with fractional erbium:yag laser ablation in scar prevention

Conditions: Intense Pulsed Light; Erbium-yttrium Aluminum Garnet Laser; Scar Prevention

Summary: the scar site was divided into 3 sites; combined ipl/fractional er:yag laser treatment site, fractional er:yag laser treatment site and untreated control site. at baseline, three lesions were randomized to ipl / fractional er:yag laser combination therapy site, fractional er:yag laser treatment alone site, and untreated control site. the laser treatment was conducted total three sessions, immediately at suture removal (baseline), 4 weeks after suture removal and 8 weeks after suture removal. the evaluation of scar site was conducted 3 months later after last treatment (20 weeks after suture removal).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of postoperative scars on the abdomen * scars were symmetrical shaped in a line of 3cm or more exclusion criteria: * uncontrolled systemic or chronic disease * hypersensitive to the ingredients * a history of other laser treatments within the past 6 months * pregnancy * lactation * recent sun exposure
diversity in patients with oab

Conditions: Overactive Bladder; Diversity; Onabotulinum Toxin A; Sacral Neuromodulation; Discrete Choice Experiment

Summary: an overactive bladder (oab) is a condition characterized by frequent en nightly voiding, small bladder capacity and the occurrence of sudden urge to void, with or without urinary incontinence. the prevalence of oab with bothersome complaints is around 11% in women and 9% in men with an increasing incidence with age. oab is not an illness or disease but nevertheless had a significant impact on both the individual as society. first-line treatment for oab consists out of behavioral and physiotherapy. anticholinergic medication can be associated to improve bothersome symptoms, but has the downside of causing unwanted side effects. if the formentioned treatment is not sufficient, second line treatment can be discussed. depending on the patient's characteristics and the physician's preference intravesical injections of botox or the implantation of a sacral neuromodulator (snm) can be considered. both options are equal and effective, but many individual differences exist in preference. regarding outcome, some factors have been described to prefer one therapy above the other, for example in case of concomitant fecal incontinence, frequent urinary tract infections,... the personal preference of doctors and patients has been investigated, but currently no study has focused on therapy preference in a culturally and linguistic divers (cald) population. the latter broadly describes a population with ethnical, cultural, religious and/or language characteristics and is a general accepted measure of diversity. in the current study, the investigators aim to describe the different (dis)advantages of both second line treatments for oab in a discrete choice experiment. the study population will consist of a diverse group of patients with oab from different hospitals. the goal is to investigate if cald patients make a different choice in treatment and what factors contribute to that decision in order to provide more tailored information regarding the treatment options in the future. taking a patient's context into account in the shared decision making between a patient and physician increases therapy compliance and satisfaction of the chosen treatment. the total questionnaire will consist out of general demographic info, the eq-5d, the international consultation on incontinence questionnaire (iciq)-oab and the discrete choice questionnaire in which patients make a choice between two fictional treatment options consisting of a combination of different therapy characteristics. the questionnaire will be translated into different languages in order to lower the threshold for participation.


Eligibility criteria:
inclusion criteria: * oab * adult exclusion criteria: * snm or botox in history
virtual environment to aid cognitive stimulation of elderly people with early alzheimer's

Conditions: Alzheimer Disease

Summary: this research was carried out with the objective of verifying the possibility of intervention through cognitive training protocols to assist in the stimulation of neurons and to delay the degradation resulting from alzheimer's disease in its initial phase. the specific objective of this research was to develop and validate a virtual environment of games (called sorrisotur) that allows the intervention of cognitive training.

sorrisotur encompasses cognitive training concepts and protocols in playful situations, which were coded in the form of 2d mini-games that are run on a computer connected to the web, and designed to stimulate cognitive domains, such as memory, executive functions, spatial-visual skills, language (expression, comprehension, reading, and writing) and personality/behavior. for the comparison of results, three groups were created; one group of elderly people with alzheimer's disease at an early stage, one group formed by healthy elderly, and another group with young people and applied mini-mental state examination (mmse) and wechsler intelligence scale for adults (wais-iii) before and after of interventions with the games.

Eligibility criteria:
inclusion criteria: * people with physical or psychological conditions allow interacting with digital games; * elderly over 60 years with mild alzheimer; * seniors over 60 healthy; * healthy youth; exclusion criteria: * people without physical or psychological conditions allow interacting with digital games; * elderly people over 60 years old who have any type of dementia other than alzheimer, or moderate or severe alzheimer;
a study to demonstrate the safety and preliminary efficacy of 18f-flt in patients with solid tumours or lymphoma

Conditions: Brain Cancer; Cancer; Solid Tumor; Lymphoma

Summary: the radiotracer 18f-flt can non-invasively assess excessive cell growth in pet scan images. tumour growth rate is a useful indicator of tumour aggression and response to treatment. imaging and measuring the cell growth with 18f-flt may be useful in monitoring response to anticancer treatment.

clinical trial is a combined phase i/ii imaging, open label, single site study in patients with known or suspected carcinoma of the lung, breast, renal cell, pancreas or brain, and with gastrointestinal malignancies, neuroendocrine tumours, or lymphoma. one 18f-flt pet scan will be performed in 10 phase i patients, and pre-injection and post-imaging blood work and vital signs will be collected. up to 5 18f-flt pet scans will be performed in 170 phase ii patients.

Eligibility criteria:
inclusion criteria: * male or female greater than or equal to 16 years of age. if female of child-bearing potential and outside of the window of 10 days since the first day of last menstrual period, a negative pregnancy test is required. * patients with known primary or suspected primary, recurrent or metastatic carcinoma of the lung, breast, renal cell, pancreas or brain (including ggm, oligodendrogliomas, and brain metastases from any primary tumour) and with gastrointestinal malignancies, neuroendocrine tumours (including carcinoid and islet cell malignancies, or lymphoma, with at least one lesion \>1 cm in diameter. * biochemical parameters as measured are required to be within 5 times the normal limits for age. * able and willing to follow instruction and comply with the protocol * provide written informed consent prior to participation in the study * karnofsky performance scale score 50-100 exclusion criteria: * previous removal of entire tumour * biochemical parameters as measured outside 5 times the normal limits for age * unable or unwilling to follow instructions and comply with the protocol * unable or unwilling to provide written informed consent prior to participation in the study * karnofsky performance scale score \< 50 * nursing or pregnant females * age less than 16 years

Keywords: 18f-flt positive emission tomography cancer
rtms for apathy clinical trial

Conditions: Alzheimer Disease; Apathy in Dementia

Summary: apathy is a common, early, and disabling symptom in dementias such as alzheimer's disease (ad) and is characterized by lack of interest and enthusiasm. both repetitive transcranial magnetic stimulation (rtms), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. this pilot study will investigate rtms as a treatment for apathy in ad in individuals receiving methylphenidate and individuals not receiving medication for apathy.


Eligibility criteria:
inclusion criteria: * major neurocognitive disorder * apathy for at least 4 weeks * stable dose of medication (\>4 weeks) that may affect cognition or behaviour * care partner who spends at least 10 hours a week with the subject exclusion criteria: * current major depressive episode * agitation, delusions, hallucination * medical contraindications to rtms * currently taking an amphetamine product * central nervous system abnormalities, tourette's syndrome, or motor tics * current participation in another clinical trial

Keywords: apathy alzheimer's disease
effect of tetracycline pleurodesis on prevention of primary spontaneous pneumothorax recurrence

Conditions: Primary Spontaneous Pneumothorax

Summary: primary spontaneous pneumothorax (psp) defines as presence of air in chest cavity occurs most commonly in young, tall, and smoker men without underlying lung disease. trends for psp treatment tend toward more invasive procedures. thoracotomy with pleurectomy and bullectomy is definitive treatment of psp which significantly reduces recurrence probability. this procedure has been reported to cause high rate of morbidity and mortality. thus video-assisted thoracoscopic surgery (vats) has become the preferred method for treatment of psp with recurrence rate of 5-10%. for persistent or recurrent cases, mechanical or chemical pleurodesis have been suggested. based on guidelines patients with large size of lesions in ct or with unstable condition should undergo surgical procedure for recurrence prevention but patients with small lesion size and stable condition can be only observed. conservative management of psp is safe and effective, but as mentioned this method has high recurrence rate. on the other hand fear of recurrence can negatively affect patients' quality of life, so that some patients prefer surgical intervention to observation management. also some studies recommend invasive treatments because of cost effectiveness of this methods. as mentioned above, chemical pleurodesis is a usual method for treatment in patients with persistent or recurrent spontaneous pneumothorax. this method has been done using variety of chemical agents including tetracycline, minocycline, blood, and talc to irritate pleura. according to different studies tetracycline has the highest efficacy between irritant agents. in current study, the investigators have aimed to assess tetracycline chemical pleurodesis through tube thoracostomy in prevention of spontaneous pneumothorax in symptom free patients with normal ct-scan following first episode of psp.


Eligibility criteria:
inclusion criteria: * first episode of primary spontaneous pneumothorax * do not have bullae in ct-scan * no history of chest trauma or thoracic surgery exclusion criteria: * history of chest trauma or thoracic surgery and start/quiting of smoking during past year. * not willing to participate in the study

Keywords: tetracycline pleurodesis
validation of ambulatory sleep test (wp200/u) compared in-lab sleep testing in cardiac subjects

Conditions: Sleep Disorders

Summary: subjects with cardiac disorders will be tested in the sleep laboratory with a conventional full-night psg recording along with wp 200/wp200u ambulatory sleep diagnostic device in a synchronized manner. the psg data will be scored manually by a trained polysomnographic scorer, according to standard criteria for this clinical routine. the data obtained by the wp200/wp200u will be analyzed automatically for rdi, ahi, sleep stages, snoring (optional) and body position (optional), in addition to parameters specific to cardiac subjects. the analysis will be performed by the wp200/wp200u software (zzzpat) and will be compared to the psg's manual scoring which serves as a "gold standard".

subjects with cardiac disorders, referred to the sleep lab will be offered to participate in the study. subjects will be asked to sign an informed consent form and will be screened for inclusion exclusion criteria. subject demographic and medical information will be acquired from the subject himself and/or from the subject's medical chart and will be recorded on the appropriate pre-study electronic case report forms. the subjects will be admitted to the clinical sleep laboratory for one night, during which they will undergo conventional full night psg recording with the standard psg channels. the wp 200/wp200u wrist device, which includes the pat and pulse oximeter probes will be worn on the wrist. the investigator will not have access to the wp200/wp200u data while scoring the psg data. during the study recording, the wp200/wp200u data will be recorded inside the device, without being displayed on the psg monitor. furthermore, the wp200/wp200u analysis is done automatically without knowledge of the psg scoring results.

Eligibility criteria:
inclusion criteria: * age between17-90 * subject is able to read understand and sign the informed consent form. * subject with diagnosed cardiac disorders and/or other comorbidity * willing to sleep with the wp200/wp200u and psg simultaneously in the sleep lab exclusion criteria: * permanent pacemaker: atrial pacing or vvi without sinus rhythm * finger deformity that precludes adequate sensor appliance. * use of one of the following medications: alpha blockers, short acting nitrates (less than 3 hours before the study)
effect of sarcopenia in stroke patients

Conditions: Stroke; Sarcopenia

Summary: primary research purpose: -prospective study to screen post stroke patients with sarcopenia and evaluate its effect on recovery secondary research purpose: * to determine the degree of sarcopenia and correlation with poor functional prognosis of stroke in the stroke patient group. * to determine the degree of sarcopenia and correlation with dixon mri of thigh muscle * to evaluate surface emg (semg)-based signals and correlation with sarcopenia * to determine the degree of sarcopenia and correlation with brain morphometric changes

patients with first-ever stroke will be enrolled and assessed for sarcopenia. the evaluation parameters will include standard sarcopenia parameters and also semg-based signals and imaging studies.

Eligibility criteria:
inclusion criteria: * patients 65 years of age or older, stroke patients with first onset within 4 weeks exclusion criteria: * patients who have not been evaluated for sarcopenia * patients with neuromuscular diseases other than stroke that may affect gait function * patients unable to conduct clinical trials according to instructions * patients with uncontrolled medical/surgical disease * patients with metal substances in the body such as cardiac pacemakers, cochlear implants, etc. * patients who have difficulty collecting blood * patients who are difficult to follow up after 6 months of onset due to moving to another area * patients who have parkinson's disease, dementia, or have a history of neuromuscular diseases such as guillain-barré syndrome or myasthenia gravis